Recomendados
Recomendados
Más contenido relacionado
Similar a Baiju Shah
Similar a Baiju Shah (20)
Más de TEDxCLE
Más de TEDxCLE (20)
Último
Último (20)
Baiju Shah
- 1. • Proudly introducing • “The Harrington Project for Discovery & Development” Bridging the Valley of Death Baiju R. Shah, CEO, BioMotiv The Harrington Project for Discovery & Development TEDxCLE April 4, 2014
- 2. 1 More Money…Fewer Medicines 1 Source: Diagnosing the decline in pharmaceutical R&D efficiency (2012); Burrill & Company analysis for PhRMA (2008) $ Bns, R&D New Drugs
- 3. 2Source Image: “Translational Research: Crossing the Valley of Death,” Nature, June 11, 2008 The Valley of Death
- 5. To Heal. To Teach. To Discover. Developing New Medicines LateClinical EarlyClinical Pre-Clinical Product Discovery
- 6. Opportunity for Innovation “There’s never been a time where we’ve had a greater outpouring of discoveries about the nature of disease. And yet paradoxically, the ability to turn that information into clinical applications seems to have slowed down. If there was ever a time when we need to figure out how to take this wonderful scientific opportunity and apply the most bold, audacious principles of innovation to make those products happen, it is now.” Dr. Francis Collins NIH Director
- 7. To Heal. To Teach. To Discover. Bridging the Valley of Death LateClinical EarlyClinical Pre-Clinical Product Discovery Valley of Death
- 8. To Heal. To Teach. To Discover. 7 Accelerating Breakthrough Discoveries into Medicines Nonprofit For-Profit Breakthrough Medicines Harrington Discovery Institute Innovation Center Research Institutions and Disease Foundations BioMotiv
- 9. To Heal. To Teach. To Discover. 8 Current Technologies THP
- 10. To Heal. To Teach. To Discover. Bridging the Valley of Death Source Image: “Translational Research: Crossing the Valley of Death,” Nature, June 11, 2008
Notas del editor
- This is a national problem, not a state problem
- This is a national opportunity in which Ohio can lead, and through leadership, Ohio can become the destination where the very best medical innovation in the nation is commercialized.To date, Ohio has not been a significant player in the development of new drugs. Not a single new drug has emerged from Ohio’s great research institutions/universities (lots of devices, no drugs). It’s not because of lack of innovation or industry; but it’s a lack of a platform that can provide a bridge from innovation to industry, connecting the dots that are already here.We have a model here that solves the problem for Ohio, and makes Ohio the destination for the best innovation from across the nation.
- 800+ opportunities have been vetted to select and support these projects throughout the country. Of this select group, the most promising initiatives will receive even greater acceleration support and through BioMotiv the companies will be established in the State of Ohio. The attraction process provided through this initiative turns the traditional economic development “company attraction” strategy around: Rather than working to land the entities that present themselves to the State as opportunities, the Harrington Project scans the nation for the best opportunities that exist, spends time working with them to develop them and takes the best of this highly refined pool.